Eckert & Ziegler Strahlen- und Medizintechnik AG

Regulatory Filings • Oct 6, 2009

News Details

Corporate | 6 October 2009 13:58

Eckert & Ziegler: Choosing the IBt Bebig Temporary Brachytherapy solution MultiSource(R) HDR Co-60 afterloader

Eckert & Ziegler Strahlen- und Medizintechnik AG / Miscellaneous

06.10.2009

Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

Berlin, 6 October 2009. Belgian Medical Device Company International
Brachytherapy S.A. (IBt Bebig), a portfolio company of Eckert & Ziegler AG
(ISIN DE0005659700) has completed the installation of a MultiSource(R)
Co-60 HDR (High Dose Rate) afterloader equipment in the Vajira Hospital in
Bangkok, Thailand. This center represents the 100th medical center in the
world that has opted for the temporary brachytherapy solution proposed by
IBt Bebig to treat certain types of cancer by internal irradiation.

The Vajira Hospital in Bangkok is expecting to use this irradiator to
primarily treat gynecological, breast and neck cancer tumors. Dr Thanatip
Tantivatana, Head of Division of Radiation Oncology, has declared: 'After a
thorough analysis and comparison of the different technologies proposed, we
have chosen the MultiSource(R) HDR brachytherapy afterloader of IBt Bebig
because of its unique technology using a miniaturized Co-60 source and the
associated very efficient, low treatment cost.'

The MultiSource(R) Co-60 High Dose Rate afterloader equipment manufactured
by IBt Bebig is now being in use in more than 20 countries around the
world. 'This installation represents an important symbolic milestone for
the group. It is also a strong indication of the increased level of
recognition and of the value of our world unique Co-60 irradiation source
technology', commented Mr. François Blondel, CEO of IBt Bebig. 'We are now
expecting to significantly expand our market coverage over the next two to
three years and proceed, over this time frame, with the installation of an
additional 100 afterloaders HDR temporary brachytherapy machines,
generating in excess of 20 million EUR of revenues for the group', he
added.

The MultiSource(R) is a medical device equipment that allows to perform the
temporary brachytherapy treatment of cancers. Using a radioactive source
(either Ir-192 or Co-60) contained and shielded in a trolley, catheters are
inserted by the physician into the body and allow for a 'temporary implant'
to be positioned directly inside the tumor ('remote afterloading'
technique).

IBt Bebig develops, produces, and sells radiation-technology products for
the treatment of cancer, in particular prostate cancer, worldwide. The
company with its approx. 150 employees is market leader in Europe for weak
radioactive prostate cancer implants. The company's head office is in
Brussels, the main production site is in Berlin. Eckert & Ziegler holds
almost 40% of the economic shares of the company and 29.9% of the voting
rights in the annual general meeting. Eckert & Ziegler owns an option for
another 21% of the annual general meeting's voting rights.

Eckert & Ziegler AG is one of the world's largest providers of isotope
component technology for radiation therapy and nuclear medicine and has
approx. 520 employees. For the current year, the company expects sales of
approx. EUR 100 million and earnings per share of approx. EUR
1.80.

Eckert & Ziegler AG, Karolin Riehle, Investor Relations, Robert-Rössle-Str.
10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, Fax -112, E-Mail: karolin.riehle@ezag.de,
www.ezag.de

06.10.2009 Financial News transmitted by DGAP

---

Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Deutschland
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700, ISIN DE0005659700
WKN: 565970, ISIN DE000A0L1L69
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Düsseldorf, Hamburg

End of News DGAP News-Service

---